Avastin Misses Key Data Point in Brain Cancer Study

From Balochistan Times (Pakistan) (January 15, 2013)

Swiss drugmaker Roche's cancer drug Avastin failed to make a
statistically significant difference to survival rates of patients
with a common form of brain cancer in a late-stage study,...

Source: Drugs.com - Pharma News - January 15, 2013 Category: Pharmaceuticals Source Type: news